The National Institutes of Health (NIH) awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), also known as eczema. No treatments are available that achieve long-term remission without side effects. The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, a protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are hallmark AD features. The researchers see the study as potentially groundbreaking in using “narrow pathway”-targeted immune interventions for not just AD, but other “allergic” inflammatory diseases of the skin or other organs, such as asthma.
-
About
-
Education
-
Journal
-
Departments
-
Resources
-
INSIGHTS
-
Topics
-
Excellence Forums
-
Conference Coverage
